Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Sheehan, Rory ^a   Hassiotis, Angela ^a   Walters, Kate ^a   Osborn, David ^a   Strydom, André ^a   Horsfall, Laura ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEALTH BEHAVIOR; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SOCIAL ASPECT; UNITED KINGDOM; VERY ELDERLY; CLINICAL PRACTICE; INTELLECTUAL DISABILITY; MENTAL DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; INTELLECTUAL DISABILITY; MALE; MENTAL DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTIONS; PSYCHOTROPIC DRUGS;

EID: 84947710694     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4326     Document Type: Article

References (51)

1. ®). American Psychiatric Publishing, 2013.
2. Buckles J, Luckasson R, Keefe E. A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003-2010. J Ment Health Res Intellect Disabil 2013;6:181-207.
3. Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil 2001;22:77-93.
4. Molyneux P, Emerson E, Caine A. Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. J Appl Res Intellect Disabil 1999;12:46-57.
5. Matson JL, Bamburg J, Mayville EA, et al. Psychopharmacology and mental retardation: a ten-year review (1990-1999). Res Dev Disabil 2000;21:263-96.
6. Tsiouris JA. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? J Intell Disabi Res 2010;54:1-16.
7. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev 2004;3:CD000377.
8. Department of Health. Transforming care: a national response to Winterbourne View Hospital. Department of Heath, 2012.
9. Stephenson C P, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust NZJ Psychiat 2013;47:74-87.
10. Ilyas S, Moncrief J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry 2012;200:393-8.
11. Deb S, Kwok H, Bertelli M, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 2009;8:181-6.
12. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7.
13. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5.
14. Lis Y, Mann R. The VAMP research multi-purpose database in the UK. J Clin Epidemiol 1995;48:431-44.
15. Chisholm J. The Read clinical classification. BMJ 1990;300:1092.
16. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database. Br J Gen Pract 2010;60:e128-36.
17. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the north. Routledge, 1988.
18. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009;18:704-7.
19. Buszewicz M, Welch C, Horsfall L, et al. Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiatry 2014;1:522-30.
20. Maulik PK, Mascarenhas MN, Mathers C, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2011;32:419-36.
21. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-51.
22. Maguire A, Blak BT, Thompson M. The importance of defning periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18:76-83.
23. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013;22:64-9.
24. National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE, 2015.
25. Brylewski J, Wiggs L. Sleep problems and daytime challenging behaviour in a community-based sample of adults with intellectual disability. J Intell Disabil Res 1999;43:504-12.
26. Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007;190:27-35.
27. Morgan VA, Leonard H, Bourke J, Jablensky A. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. Br J Psychiatry 2008;193:364-72.
28. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PloS One 2013;8:e82365.
29. Rait G, Walters K, Grifn M, Buszewicz M, Petersen I, Nazareth I. Recent trends in the incidence of recorded depression in primary care. Br J Psychiatry 2009;195:520-4.
30. Walters K, Rait G, Grifn M, Buszewicz M, Nazareth I. Recent trends in the incidence of anxiety diagnoses and symptoms in primary care. PloS One 2012;7:e41670.
31. Richards M, Maughan B, Hardy R, Hall I, Strydom A, Wadsworth M. Long-term afective disorder in people with mild learning disability. Br J Psychiatry 2001;179:523-7.
32. Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. An epidemiological investigation of afective disorders with a population-based cohort of 1023 adults with intellectual disabilities. Psychol Med 2007;37:873-82.
33. Holden B, Gitlesen JP. A total population study of challenging behaviour in the county of Hedmark, Norway: prevalence, and risk markers. Res Dev Disabil 2006;27:456-65.
34. McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviours in people with intellectual disabilities: a meta-analytic study. J Intell Disabil Res 2003;47:405-16.
35. Felce D, Kerr M, Hastings RP. A general practice-based study of the relationship between indicators of mental illness and challenging behaviour among adults with intellectual disabilities. J Intell Disabil Res 2009;53:243-54.
36. Holden B, Gitlesen JP. Prevalence of psychiatric symptoms in adults with mental retardation and challenging behaviour. Res Dev Disabil 2003;24:323-32.
37. De Winter C, Jansen A, Evenhuis H. Physical conditions and challenging behaviour in people with intellectual disability: a systematic review. J Intell Disabil Res 2011;55:675-98.
38. Lundqvist L-O. Prevalence and risk markers of behavior problems among adults with intellectual disabilities: a total population study in Örebro County, Sweden. Res Dev Disabil 2013;34:1346-56.
39. Davies L, Oliver C. The age related prevalence of aggression and self-injury in persons with an intellectual disability: a review. Res Dev Disabil 2013;34:764-75.
40. Strydom A, Livingston G, King M, Hassiotis A. Prevalence of dementia in intellectual disability using diferent diagnostic criteria. Br J Psychiatry 2007;191:150-7.
41. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4:e006135.
42. Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004;25:509-21.
43. DeKuijper G, Hoekstra P, Visser F, Scholte F, Penning C, Evenhuis H. Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription. J Intell Disabil Res 2010;54:659-67.
44. Tsiouris JA, Kim S-Y, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative fndings from a large scale study. J Autism Dev Disord 2013;43:719-31.
45. Hsu S-W, Chiang P-H, Chang Y-C, Lin J-D, Tung H-J, Chen C-Y. Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: a nationwide outpatient service study, 1997-2007. Res Dev Disabil 2014;35:364-72.
46. Glover G, Bernard S, Branford D, Holland A, Strydom A. Use of medication for challenging behaviour in people with intellectual disability. Br J Psychiatry 2014;205:6-7.
47. Tyrer P, Cooper S-A, Hassiotis A. Drug treatments in people with intellectual disability and challenging behaviour. BMJ 2014;349:g4323.
48. Lennox N, Taylor M, Rey-Conde T, Bain C, Purdie D, Boyle F. Beating the barriers: recruitment of people with intellectual disability to participate in research. J Intell Disabil Res 2005;49:296-305.
49. Sawyer A, Lake JK, Lunsky Y, Liu S-K, Desarkar P. Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review. Res Autism Spectr Disord 2014;8:803-13.
50. Matson JL, Mahan S. Antipsychotic drug side-efects for persons with intellectual disability. Res Dev Disabil 2010;31:1570-6.
51. Heslop P, Blair P, Fleming P, Hoghton M, Marriott A, Russ L. The confdential inquiry into prematured deaths of people with learning disabilities in the UK: a population-based study. Lancet 2014;383:889-95.